Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)

The Phase 1 HVTN 300 study demonstrated that an adjuvanted CH505 TF chimeric Env trimer immunogen is safe and effectively elicits CD4 binding site-directed antibodies, including precursors of broadly neutralizing antibodies, in healthy adults.

The Gist

The Big Picture: Trying to Teach the Body to Fight HIV

Imagine the HIV virus is a master thief wearing a very tricky, shape-shifting disguise (called the Envelope or Env). To stop the thief, our immune system needs to create a "Wanted Poster" (an antibody) that recognizes the thief's face no matter what disguise he wears.

Scientists have been trying to design a vaccine that teaches the immune system to spot the thief's most vulnerable spot: the CD4 Binding Site. Think of this spot as the thief's "master key" that he uses to pick the lock on human cells. If we can make an antibody that jams that keyhole, the thief can't get in.

The problem? The immune system usually ignores this keyhole because it's hidden or hard to reach. This study (HVTN 300) was a "first-in-human" test to see if a new, specially designed vaccine could train the immune system to find and attack that specific keyhole.

---

The Vaccine: A "Trojan Horse" with a Booster

The scientists created a special vaccine ingredient called the CH505 TF chTrimer.

• The Shape: Imagine a three-legged stool (a trimer). The legs are made of a stable, unbreakable material (BG505), but the seat of the stool is made from a specific piece of the HIV virus (CH505) that looks exactly like the "master key" the scientists want to target.
• The Adjuvant (The Booster): The vaccine wasn't just the stool; it was mixed with a powerful "wake-up call" called 3M-052-AF. Think of this like a loud siren or a spicy pepper that wakes up the immune system and says, "Hey! Look at this! This is dangerous! Go make weapons against it!"

The Experiment: Who Got It and What Happened?

The study took place in Boston with 13 healthy adults. They got this vaccine five times over a year (at months 0, 2, 4, 8, and 12).

1. The Safety Check (The "Pain Factor")

The vaccine worked, but it was a bit rough on the body.

• The Analogy: Imagine getting a flu shot, but the shot feels like someone is poking you with a hot needle and then giving you a headache and body aches for a day.
• The Result: Most people had mild to moderate soreness or fatigue. However, for 5 out of 13 people, the reaction was so strong (severe pain or feeling very sick) that they decided to stop the study and didn't get the later shots.
• The Good News: No one had life-threatening reactions. It was safe, just uncomfortable.

2. Did It Wake Up the Immune System? (The "Training")

Yes! The vaccine successfully woke up the immune system.

• B-Cells (The Soldiers): The vaccine trained the body's "soldiers" (B-cells) to recognize the specific keyhole on the HIV virus.
• The Result: After the third and fifth shots, 100% of the people who stayed in the study had these trained soldiers.
• The Catch: While the soldiers were trained, they weren't perfect yet. They were like recruits who know the enemy's face but haven't learned how to shoot the target effectively yet.

3. Did It Create "Super Weapons"? (The Neutralization Test)

The ultimate goal is to create Broadly Neutralizing Antibodies (bnAbs)—weapons that can stop any version of HIV.

• The Test: Scientists took the blood of the participants and mixed it with different strains of HIV to see if it could stop the virus.
• The Result:
  • 4 out of 11 participants showed signs of having created the precursors (the early drafts) of these super-weapons.
  • Specifically, they found antibodies that targeted the "HCDR3-binder" type of keyhole (a specific way of jamming the lock).
  • However: The weapons weren't strong enough yet to stop the virus in a real-world scenario. The blood didn't neutralize a wide range of HIV strains, just a few specific ones.

The "Why Didn't It Work Better?" Mystery

The scientists noticed something interesting when they looked at the antibodies under a high-powered microscope (Electron Microscopy).

• The Analogy: Imagine the vaccine was supposed to teach the immune system to attack the "seat" of the three-legged stool (the keyhole).
• What Actually Happened: The immune system mostly attacked the "legs" of the stool (the base) or pieces of the stool that fell apart.
• The Problem: The vaccine was so strong that it actually caused the stool to break apart (dissociate). The immune system got distracted by the broken pieces and the legs, ignoring the important seat they were supposed to target.
• The Conclusion: Repeating the same shot five times didn't fix this. In fact, it seemed to make the immune system focus more on the wrong parts (the legs) and less on the right part (the seat).

The Bottom Line

What did we learn?

1. It's Safe: The vaccine didn't hurt anyone permanently, though it was quite painful for some.
2. It Works (Sort of): It successfully taught the immune system to find the right target (the CD4 binding site) in the majority of people.
3. It's Not Ready Yet: The antibodies created weren't strong or broad enough to stop HIV on their own. The vaccine design needs to be tweaked so the immune system focuses on the "seat" and not the "legs."

The Future:
This study is like a pilot test for a new car engine. The engine runs, but it's a bit loud and smokes a little. The scientists now know how to build it, but they need to refine the design (maybe change the adjuvant or the shape of the protein) to make it smoother and more powerful before they can put it on the road to fight HIV.

They are now looking at ways to stop the immune system from getting distracted by the "legs" of the stool and to make the "wake-up call" (adjuvant) less painful for the patients.

Technical Summary

1. Problem Statement

The development of an effective HIV-1 vaccine remains a critical unmet medical need, primarily due to the virus's high mutation rate and the difficulty in eliciting Broadly Neutralizing Antibodies (bnAbs). While bnAbs targeting the CD4 binding site (CD4bs) have been isolated from infected individuals, inducing them via vaccination is challenging.

• The Gap: Previous strategies have successfully targeted "CD4-mimicking" bnAbs (e.g., VRC01-class) which use specific heavy chain genes (VH1-2 or VH1-46). However, no clinical trial has successfully targeted the second major class of CD4bs bnAbs: the HCDR3-binder type (exemplified by the CH103 lineage).
• The Challenge: The CH103 lineage is a promising target because it requires fewer somatic hypermutations and improbable mutations to achieve breadth compared to VRC01-class antibodies. However, inducing the naive B-cell receptors (BCRs) for this lineage in humans has not been demonstrated. Furthermore, previous trimer immunogens often elicit off-target antibodies (e.g., to the trimer base) or fail to overcome immunodominance issues.

2. Methodology

Study Design:

• Trial: HVTN 300, a first-in-human, open-label Phase 1 clinical trial.
• Population: 13 healthy adults (aged 18–55) enrolled at a single site in Boston, USA.
• Vaccination Regimen: Participants received 5 doses (Months 0, 2, 4, 8, and 12) of the immunogen administered intramuscularly (bilateral deltoid injections).

Immunogen and Adjuvant:

• Immunogen: CH505 TF chTrimer. A stabilized chimeric SOSIP Env trimer. It features the N-terminal sequence of the CH505 Transmitted/Founder (TF) gp120 (specifically designed to bind the naive BCR of the CH103 lineage) transplanted into the BG505 SOSIP gp41 scaffold.
• Adjuvant: 3M-052-AF (a lipid-modified TLR7/8 agonist) combined with Alum. This combination was selected based on prior non-human primate (NHP) data showing superior tier 2 neutralization compared to other adjuvants.

Assessments:

• Safety: Monitoring of solicited local/systemic reactogenicity (7 days post-vaccination) and unsolicited adverse events (AEs) for 12 months.
• Immunogenicity:
  • T-cell responses: Intracellular cytokine staining (ICS) for CD4+ and CD8+ T cells (IFN-γ/IL-2).
  • B-cell responses: Flow cytometry for CH505-specific memory B cells.
  • Binding Antibodies: Binding Antibody Multiplex Assay (BAMA) and ELISA against various Env constructs (trimer, gp120, V1/V2).
  • Neutralization: TZM-bl pseudovirus neutralization assays against autologous (Tier 1/2) and heterologous Tier 2 viruses.
  • Epitope Mapping:
    • EMPEM: Electron Microscopy-based Polyclonal Epitope Mapping to visualize antibody binding sites on the trimer.
    • Blocking Assays: Competition ELISAs to determine if serum antibodies block known bnAbs (e.g., CH103, VRC01, sCD4).
    • Knockout Neutralization: Using engineered pseudoviruses with specific CD4bs mutations (e.g., D368, D371, S365, N280D) to detect neutralization signatures specific to bnAb precursors.

3. Key Contributions

• First-in-Human Targeting of HCDR3-binder Precursors: This is the first clinical trial to specifically attempt to prime the naive B-cell receptors of the CH103-class (HCDR3-binder) CD4bs bnAbs in humans.
• Adjuvant Evaluation: It evaluates the safety and immunogenicity of the potent 3M-052-AF/Alum adjuvant system in a human HIV trimer vaccine context.
• Comprehensive Epitope Mapping: The study utilizes a multi-modal approach (EMPEM, blocking, and knockout neutralization) to dissect the polyclonal serum response, revealing the dominance of off-target responses versus on-target precursors.
• Longitudinal Dosing Analysis: The study investigates whether repeated homologous boosting (up to 5 doses) can overcome immunodominance and broaden the response, a strategy often hypothesized but rarely tested to this extent in humans with this specific immunogen.

4. Results

Safety and Reactogenicity:

• The vaccine was generally safe with no Serious Adverse Events (SAEs) related to the vaccine.
• Reactogenicity: High rates of local and systemic reactogenicity were observed. Local pain/tenderness was common. Systemic symptoms (fatigue, myalgia, headache) were mostly mild-to-moderate, but 5 participants experienced severe (Grade 3) systemic symptoms.
• Dropouts: Due to reactogenicity, 5 participants discontinued the study before completing all 5 doses (5/13 enrolled stopped early).

Immunogenicity:

• T-Cells: Robust CD4+ T-cell responses (>80% of participants) were induced, peaking after the 3rd dose. CD8+ responses were negligible.
• B-Cells: 100% of participants developed CH505-specific memory B cells after the 3rd dose.
• Binding Antibodies: All participants developed binding antibodies to the vaccine-matched trimer and gp120. Responses peaked after the 3rd dose and did not significantly increase with doses 4 and 5.
• Neutralization:
  • Autologous: 3/9 participants developed Tier 2 autologous neutralizing antibodies (ID80 > 10) against the CH505 TF virus.
  • Heterologous: No significant heterologous Tier 2 neutralization was observed against a global panel.
• CD4bs Specificity (The Critical Finding):
  • EMPEM: The majority of serum IgG bound to the trimer base or internal protomer epitopes (exposed due to trimer dissociation). No CD4bs binding was visualized by EMPEM, suggesting these antibodies are low abundance.
  • Blocking: Serum from 7/7 participants blocked sCD4 and CH103-lineage bnAbs, indicating CD4bs-directed antibodies were present.
  • Neutralization Signatures: Using engineered pseudoviruses with CD4bs knockouts, 4 out of 11 participants showed a neutralization signature indicative of CH103-like (HCDR3-binder) precursors. One participant showed a signature for CH235-like (CD4-mimicking) precursors.
  • Dose Effect: The frequency of participants with these "on-target" neutralization signatures did not increase between the 3rd and 5th doses.

5. Significance and Conclusions

• Proof of Concept: The study successfully demonstrated that the CH505 TF chTrimer + 3M-052-AF/Alum can induce serum antibodies capable of neutralizing HIV strains designed to detect CH103-class bnAb precursors in a subset of humans. This validates the feasibility of targeting the HCDR3-binder lineage.
• Immunodominance Challenge: The study highlights a major hurdle: the immune response is dominated by off-target antibodies (trimer base, internal epitopes) and the trimer itself appears unstable in vivo (dissociating into protomers), exposing non-neutralizing epitopes. Repeated homologous boosting failed to shift the response toward broader neutralization or increase the frequency of on-target precursors.
• Safety vs. Efficacy Trade-off: The potent adjuvant (3M-052-AF) elicited strong immune responses but also significant reactogenicity, leading to high dropout rates. Future iterations may require lower adjuvant doses or less reactogenic formulations.
• Future Directions: The results suggest that a single immunogen, even with multiple boosts, is insufficient to induce broad neutralization. The authors conclude that sequential immunization strategies (using different immunogens to guide B-cell maturation) and trimer stabilization (to prevent dissociation and exposure of internal epitopes) are necessary next steps.
• Complementary Data: The paper notes that a companion study analyzing the B-cell repertoires of these participants (Chen Hao et al.) confirmed the presence of CH103-like B-cell lineages in 7/10 vaccinees, suggesting that while serum neutralization was low, the cellular priming was successful.

In summary, HVTN 300 is a landmark study that successfully primed a difficult-to-target bnAb lineage in humans but also underscored the complexity of overcoming immunodominance and the need for refined immunogen design and sequential vaccination strategies to achieve broad protection.